Neuroinflammation And Rare Disease Therapies Will Drive Long-Term Opportunity In Innate Immunity

Catalysts

About INmune Bio

INmune Bio develops platform immunotherapies that modulate inflammation and innate immunity across neurodegenerative disease, oncology and rare inflammatory disorders.

What are the underlying business or industry changes driving this perspective?

• Approaching CORDStrom marketing submissions in the U.K. and U.S. positions INmune Bio for its first potential commercial product in a high unmet need rare disease, which could drive an inflection in revenue once pricing and reimbursement are secured.
• Growing recognition of chronic inflammation as a core driver of neurodegeneration strengthens the strategic fit of XPro's neuroinflammation-focused mechanism, improving the odds of regulatory support and future partnership-driven funding that can accelerate earnings growth.
• Industry demand for systemic treatments that complement or improve upon topical and gene therapies in RDEB supports CORDStrom's systemic profile, which can enable broader patient use and premium pricing, supporting higher net margins relative to more complex gene therapies.
• Increasing use of biomarker and MRI-based enrichment in Alzheimer's trials aligns with XPro's focus on highly inflamed patient subgroups, which may enable smaller, more efficient registration studies and lower development spend per dollar of future revenue.
• Rising adoption of off-the-shelf cell and innate immune therapies, together with INmune Bio's scalable, cost-conscious manufacturing design for CORDStrom and INKmune, supports structurally attractive gross margins as volumes scale and improves long-term operating leverage.

Assumptions

How have these above catalysts been quantified?

• INmune Bio currently has no revenue. Analysts are forecasting revenue to reach $43.2 million by July 2029.
• Analysts are not forecasting that INmune Bio will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate INmune Bio's profit margin will increase from 0.0% to the average US Biotechs industry of 17.2% in 3 years.
• If INmune Bio's profit margin were to converge on the industry average, you could expect earnings to reach $7.4 million (and earnings per share of $0.28) by about July 2029, up from -$41.6 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 30.9x on those 2029 earnings, up from -1.1x today. This future PE is greater than the current PE for the US Biotechs industry at 16.9x.
• Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.17%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• CORDStrom and XPro still depend on favorable regulatory decisions in both the U.K. and U.S., and any delay, request for additional trials or outright rejection in RDEB or Alzheimer's could significantly postpone or reduce expected product launches, limiting future revenue and earnings growth.
• The company currently generates losses and expects to fund operations only into Q4 2026, so if capital markets remain tight or partnership deals do not materialize after key 2026 FDA and MHRA meetings, INmune Bio may be forced to raise dilutive equity or cut programs, pressuring earnings and constraining long-term revenue potential.
• Long-term competition trends in rare disease and neurodegeneration, including topical gene therapies for RDEB and multiple large-cap efforts in Alzheimer's, could capture key patient segments or pricing power, which would cap CORDStrom and XPro market share and compress net margins even if the products reach approval.
• The INKmune program has shown biologic activity but limited tumor response in heavily pretreated patients, and shifting into randomized Phase II trials in better risk disease will require additional investment with uncertain outcomes, which could increase research and development spend without a commensurate uplift in future earnings.
• Manufacturing scale up for cell and innate immune therapies is complex, and if potency assays, batch consistency or commercial CGMP operations for CORDStrom or INKmune face setbacks similar to those seen across the broader cell therapy industry, this could delay launches, raise cost of goods and structurally reduce long-term gross margins and profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $7.0 for INmune Bio based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.0, and the most bearish reporting a price target of just $4.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $43.2 million, earnings will come to $7.4 million, and it would be trading on a PE ratio of 30.9x, assuming you use a discount rate of 7.2%.
• Given the current share price of $1.72, the analyst price target of $7.0 is 75.4% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.